Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
5.37
+0.37 (7.40%)
Market open: Aug 12, 2026, 1:54 PM EDT
5.11
+0.11 (2.14%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
| Name | Position |
|---|---|
| Dr. Pramod Gupta Ph.D. | Executive Vice President of Pharmaceutical and Business Operations |
| Dr. Shalabh K. Gupta M.D., MPA | Founder, Chairman, CEO & President |
| Mr. Douglas Jermasek M.B.A. | Executive Vice President of Corporate Strategy |
| Mr. John W. Townsend CPA | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-07-02 | 8-K | ea0296892-8k_unicycive.htm |
| 2026-06-22 | DEFA14A | ea0295382-8k_unicycive.htm |
| 2026-06-22 | 8-K | ea0295382-8k_unicycive.htm |
| 2026-06-05 | S-3 | ea0291789-s3_unicycive.htm |
| 2026-06-05 | 8-K | ea0291976-8k_unicycive.htm |
| 2026-05-12 | 8-K | ea0290277-8k_unicycive.htm |
| 2026-05-12 | 10-Q | ea0289336-10q_unicycive.htm |
| 2026-05-06 | S-8 | ea0288752-s8_unicycive.htm |
| 2026-04-06 | 8-K | ea0285174-8k_unicycive.htm |
| 2026-03-30 | 8-K | ea0283942-8k_unicycive.htm |